Abstract:Objectives: Thrombosis and inflammation are associated with the pathogenesis of pulmonary arterial hypertension (PAH). However, there are no solid data supporting the involvement of platelet and leukocyte activation and interaction in PAH. The present study thus investigated the activation and interaction of circulating platelets and leukocytes in a rat model of monocrotaline (MCT)-induced pulmonary hypertension. Methods: Mean pulmonary arterial pressure (mPAP) was monitored in rats (n = 24) before and 2, 3 and 7 weeks after MCT (60 mg/kg)injection. In parallel, activation of circulating platelets and leukocytes and platelet-leukocyte aggregates were measured by whole-blood flow cytometry. Results: Two weeks after MCT injection, mPAP had increased significantly, i.e. from 11.25 ± 0.92 mm Hg at baseline to 15.71 ± 1.66 mm Hg (p < 0.05), and it had increased even further at week 7 (26.83 ± 3.29 mm Hg; p < 0.01). Fibrinogen binding of circulating platelets had increased from the basal level of 1.45 ± 0.61 to 4.08 ± 1.59% 3 weeks after MCT injection (p < 0.01). Platelet responsiveness to ADP was also significantly enhanced. CD11b expression of circulating neutrophils was elevated; i.e. mean fluorescence intensity increased from 1.67 ± 0.38 before MCT injection to 2.37 ± 0.31 3 weeks after MCT injection (p < 0.01), and N-formyl-methionyl-leucyl-phenylalanine (1 × 10–7M) stimulation induced more marked elevation of neutrophil CD11b expression in MCT-treated animals. Circulating platelet-neutrophil aggregates were already increased 2 weeks after MCT treatment (14.93 ± 4.22%; p < 0.01) compared to baseline (6.01 ± 2.91%) and remained elevated at 3 weeks (15.19 ± 4.78%; p < 0.01). Conclusions: MCT-induced PAH in rats is associated with increased platelet and leukocyte activation and platelet-leukocyte interaction in vivo, which may play an important role in the pathogenesis of PAH.

[Renal diseases and platelet activating factor]

Systemic Evaluation of Platelet and Leukocyte Activation and Interaction in A Rat Model of Pulmonary Arterial Hypertension

Role of platelet-activating factor receptor in adhesion and invasion of Aggregatibacter actinomycetemcomitans in human umbilical vein endothelial cells

Determination of the Platelet Activating Factor in Silicotic Patients and Its Effect on Fibroblasts

The Role of Plateletactivating Factor in Hepatic Ischemiareperfusion Injury and the Protective Effect of Anisodamine

Targeting the Platelet-Activating Factor Receptor (PAF-R): Antithrombotic and Anti-Atherosclerotic Nutrients

Release, purification, and characterization of platelet-activating factor (PAF)

Effects of the specific platelet-activating factor antagonists, BN 52021 and BN 52063, on various experimental gastrointestinal ulcerations

Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases

Effect of a Platelet-Activating Factor Antagonist on Pancreatitis-Associated Gut Barrier Dysfunction in Rats.

Chains of death

Pancreatitis-associated Pulmonary Injury: Effects of Lexipafant, a Platelet-Activating Factor Antagonist

The Effects of Platelet-Activating-Factor and Retinoic Acid on the Expression of Elam-1 and Icam-1 and the Functions of Neutrophils

Effects of inhaled PAF in humans on circulating and bronchoalveolar lavage fluid neutrophils. Relationship to bronchoconstriction and changes in airway responsiveness

Role of Platelet-Activating Factor in the Pathogenesis of Chronic Spontaneous Urticaria

Lexipafant - a glimmer of hope for pancreatitis

Endothelium from diverse vascular sources synthesizes platelet-activating factor

Platelet-activating factor (PAF)-antagonists of natural origin

Effects of Platelet-Activating Factor (PAF) on the Mechanical Activities of Lower Urinary Tract and Genital Smooth Muscles

Platelet-activating factor. A putative mediator in central nervous system injury?

Periplaneta Americana Extract May Attenuate Renal Fibrosis through Inhibiting Janus Tyrosine Kinase 2/Signal Transducer and Activator of Transcription 3 Pathway